Effect of cumminum cyminum capsule on dysmenorrhea and menstrual bleeding in IUD users.

Investigation effect of cumminum cyminum capsule on dysmenorrhea and menstrual bleeding in IUD users.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201208106284N4

Enrollment

200

Registered

2012-08-15

Start date

2012-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Secondary dysmenorrhoea in IUD users. Condition 2: Menstrual bleeding in IUD users. Secondary dysmenorrhoea Excessive and frequent menstruation with regular cycle,Excessive and frequent menstruation with irregular cycle

Interventions

Intervention 1: Cumminum cyminum powder, 500 mg capsule oral, 7days from starting menstrual bleeding , two capsule three times daily. Intervention 2: Mefenamic Acid capsules,250 mg capsule,7 days from

Treatment - Drugs

Cumminum cyminum powder, 500 mg capsule oral, 7days from starting menstrual bleeding , two capsule three times daily

Mefenamic Acid capsules,250 mg capsule,7 days from starting menstrual bleeding,two capsules three times daily,similar in shape and package as same as intervention group

Eligibility

Sex/Gender

Female

Age

15 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: contraceptive method is cupper T380 IUD; 6 months up to 3 years passed after the IUD insertion; with moderate or severe dysmenorrhea assessed by verbal multi-dimensional scoring system; absence of known gastrointestinal, hepatic, thyroid, nephrogenic and cardiovascular disease; absence of NSAIDS and cumin sensitivities. Exclusion criteria: using the capsules not according to medical prescription; taking any kind of medical or herbal analgesic or hormonal drugs during intervention ans removal of IUD.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of dysmenorrhea. Timepoint: At the start of menstrual bleeding,24 hours,48hours,72hours and 7 days after starting menstrual bleeding ,before and after interven tion. Method of measurement: Visual analgue scale (VAS).;Menstrual bleeding. Timepoint: During the menstrual bleeding, before and after intervention. Method of measurement: Pictorial blood loss assessment chart(higham chart).	—

Secondary

Measure	Time frame
Severity of physical symptom of dysmenorrhea. Timepoint: At the end of first month,third month and fifth month of research. Method of measurement: Check list of physical symptom of dysmenorrhea.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Modarres

Tehran University of Medical Sciences

modarres@sina.tums.ac.ir+98 21 6692 7171

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026